Sirtuin 1 (Sirt1) and Sirtuin 2 (Sirt2) belong to the family of NAD þ (nicotinamide adenine dinucleotide-positive)-dependent class III histone deacetylases and are involved in regulating lifespan. As cancer is a disease of ageing, targeting Sirtuins is emerging as a promising antitumour strategy. Here we present Salermide (N-{3-[(2-hydroxynaphthalen-1-ylmethylene)-amino]-phenyl}-2-phenyl-propionamide), a reverse amide with a strong in vitro inhibitory effect on Sirt1 and Sirt2. Salermide was well tolerated by mice at concentrations up to 100 lM and prompted tumour-specific cell death in a wide range of human cancer cell lines. The antitumour activity of Salermide was primarily because of a massive induction of apoptosis. This was independent of global tubulin and K16H4 acetylation, which ruled out a putative Sirt2-mediated apoptotic pathway and suggested an in vivo mechanism of action through Sirt1. Consistently with this, RNA interference-mediated knockdown of Sirt1, but not Sirt2, induced apoptosis in cancer cells. Although p53 has been reported to be a target of Sirt1, genetic p53 knockdowns showed that the Sirt1-dependent proapoptotic effect of Salermide is p53-independent. We were finally able to ascribe the apoptotic effect of Salermide to the reactivation of proapoptotic genes epigenetically repressed exclusively in cancer cells by Sirt1. Taken together, our results underline Salermide's promise as an anticancer drug and provide evidence for the molecular mechanism through which Sirt1 is involved in human tumorigenesis.
Introduction
Histone deacetylases (HDACs) comprise a superfamily of proteins involved in a wide range of cellular functions, which include regulation of transcription (Minucci and Pelicci, 2006; Xu et al., 2007) . Histone deacetylases are divided into four classes (I-IV) and regulate the expression and activity of numerous proteins involved in cancer (Glozak and Seto, 2007) , which makes them promising anticancer targets (Minucci and Pelicci, 2006; Marks, 2007; Marks and Breslow, 2007) . Indeed, several class I, II and IV HDAC inhibitors are currently being tested in phase I, II (reviewed in Marks, 2007 , Marks and Breslow, 2007 and Xu et al., 2007 and III (http://clinicaltrials.gov) clinical trials and one inhibitor, suberoylanilide hidroxamic acid (SAHA), is already on market.
Class III HDACs were discovered more recently and their activity is not affected by class I, II and IV inhibitors (Xu et al., 2007) . They include two members of the Sirtuin family of NAD þ -dependent deacetylases: Sirtuin 1 (Sirt1) and Sirtuin 2 (Sirt2). They are involved in multiple cellular events, including transcriptional silencing, chromatin remodelling, mitosis and lifespan duration (Longo and Kennedy, 2006) . In mammals, substrates for Sirt1 include histones (mainly lysine 16 of histone H4) (Vaquero et al., 2004; Pruitt et al., 2006) , but also key transcription factors, such as p53 and forkhead transcriptional factors (reviewed in . Sirt2 was initially reported to be a cytoplasmic tubulin deacetylase (North et al., 2003) and has subsequently been shown to deacetylate K16H4 at a global level (Vaquero et al., 2006) . Sirt1 and Sirt2 functions are frequently altered in cancer cells (reviewed in and for this reason they are starting to be considered as targets for antitumorigenic therapy.
The first-known Sirtuin inhibitors can be classified into two groups: the substances that inhibit NAD þ dependent reactions in general, such as nicotinamide (Bitterman et al., 2002; Avalos et al., 2005) , and Sirtuinspecific inhibitors, such as splitomicin (Bedalov et al., 2001) , sirtinol (Ota et al., 2006) , cambinol (Heltweg et al., 2006) , dihydrocoumarin (Olaharski et al., 2005) and some indoles (Napper et al., 2005) . Their common feature is that they have antitumour properties. However, their effects are generally dependent on the tumour type and stress conditions, the molecular mechanisms of action are varied or are still unclear, and the effect on non-tumorigenic samples has not been studied thoroughly. Here we describe the synthesis and mechanism of action of Salermide (N-{3-[(2-hydroxy-naphthalen-1-ylmethylene)-amino]-phenyl}-2-phenyl-propionamide), a new molecule with a potent inhibitory effect on Sirt1 and Sirt2.
Results and discussion
Design and synthesis of Salermide One of the Sirtuin inhibitors with the strongest antitumour activity is sirtinol (Grozinger et al., 2001) . However, the inhibitory activity of sirtinol on Sirt1, one of the most important Sirtuin targets in cancer, and that has been shown to be unregulated in many tumour types, is much lower than that of Sirt2 (Mai et al., 2005) and weak in general terms. Thus, we undertook molecular modelling to modify sirtinol's structure rationally in order to generate a stronger Sirtuin inhibitor. Sirtinol has a 2-hydroxy-1-naphthaldehyde moiety linked to a 2-amino-N-(1-phenylethyl) benzamide portion through an aldimine linkage. In considering the 3D structure of the Sirtuin C-pocket (Protein Data Bank Entry 1J8F), we wondered whether by changing the amide moiety borne by sirtinol into a reverse amide and finally shifting the amide side chain from the 2 0 to the 3 0 position of the phenyl ring a molecule that more strongly inhibited Sirtuins would be produced as it would be better adapted to their enzymatic active centre (Figure 1a ). To test this hypothesis, we modelled the complexes of sirtinol and its reverse amide regioisomer, which we call Salermide , with human Sirt2-HDAC by docking these two ligands onto the C-pocket of Sirt2 structure (Protein Data Bank Entry 1J8F) and then minimizing the energy of the complex. According to these modelling studies, the binding mode and residues involved are quite well conserved for these two small molecules (Figure 1b) , the hydrophobic p-p contacts being maintained with the same residues: F119 and H187. However, the change of the amide moiety borne by sirtinol into a reverse amide in Salermide places the key chemical features for this functionality at different spatial orientations. Thus, a polar interaction is missed by sirtinol: the hydrogen bridge between the oxygen of the amide and the Q167 side chain. However, this is retained by Salermide, suggesting that this drug could constitute a better inhibitor than sirtinol, as earlier experiments showed that Q167 is crucial for HDAC-Sirt2 activity (Finnin et al., 2001) . In addition, it is noted that these key binding residues also match one of those reported for EX527 and Sirt1, Q345 (Q167 correspondingly on Sirt2) (Huhtiniemi et al., 2006) . Quantification of their corresponding interactions with Sirt2, docking fitness function and a more detailed analysis after energy minimization suggests that Salermide-the stronger inhibitor-may have a higher binding affinity than sirtinol. We then synthesized the derivative Salermide by condensation between the commercially available 2-hydroxy-1-naphthaldehyde and the N-(3-amino-phenyl)-2-phenyl-propionamide, which is prepared by reacting 2-phenylpropionic acid activated with BOPreagent with 1,3-phenylenediamine under basic conditions ( Figure 1c ).
Salermide inhibits Sirt1 and Sirt2 in vitro
To evaluate the in vitro inhibitory potential of Salermide on Sirt1 and Sirt2, we incubated recombinant Histagged human Sirt1 and Sirt2 proteins (Figure 2a ) with increasing amounts of Salermide and measured HDAC activity with a fluorescent assay (Figure 2b and Supplementary Figure 1 online). We used sirtinol as the reference drug. When tested against Sirt1, Salermide showed a dose-dependent inhibition that rose to 80% at 90 mM (Supplementary Figure 1 online) . The same concentration of sirtinol resulted in a reduction of Sirt1 activity of o5% (Figure 2b ). Compared with Sirt1, Salermide was even more efficient at inhibiting Sirt2, with 80% inhibition at 25 mM (Figure 2b ). At this concentration, sirtinol did not inhibit Sirt2. Thus, as predicted by the 3D modelling, Salermide is a stronger Sirtuin inhibitor than sirtinol and, more importantly, it is able to inhibit most of the Sirt1 activity (80%) at a concentration of 100 mM, whereas the same concentration of sirtinol has a much smaller effect.
Salermide induces apoptosis in cancer but not in normal cells
Having corroborated the strong in vitro-inhibitory effect of Salermide on Sirt1 and Sirt2, we evaluated its potential antitumour effect. To this end, we incubated six cancer cell lines derived from leukaemia (MOLT4, KG1A, K562), lymphoma (Raji), colon (SW480) and breast (MDA-MB-231) primary malignancies in the presence of increasing concentrations of Salermide, and quantified cell proliferation with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. We used MRC5 in vitro-cultured fibroblasts as non-tumorigenic control samples. Treatment with 100 mM Salermide for 24 h caused a decrease in the number of cells of all the cancer samples but not in the number of non-tumorigenic MRC5 cells (Figure 2c and Supplementary Table 1 online). The reduction in the number of cells was dependent on the cell type, as shown by the half-maximal inhibitory concentration (IC50 index) (Figure 2d ). The strongest effects were observed in the leukaemia cell lines MOLT4 (Figure 2e ) and KG1A in which, after 72 h of incubation with 100 mM Salermide, only 10-20% of the initial cultured cells were viable (Supplementary Table 1 Figure 2d ).
To determine the cellular pathways by which Salermide exerts its antitumour-specific effects, we studied its action on apoptosis and cell-cycle progression in the same cell lines as used for the proliferation experiments. The classical class I, II and IV HDAC inhibitors induce tumour-cell death, with all of the biochemical and morphological characteristics of apoptosis (Mariadason, 2008) . The earlier described class III HDAC inhibitors can also induce apoptosis, although the effect depends on the tumour type and stress conditions (Heltweg et al., 2006) . Other Sirtuin inhibitors have been shown to induce senescent-like growth arrest in breast and lung cancer cell lines (Ota et al., 2006) . Salermide induced strong apoptosis without any evident effect on the cell cycle (data not shown) in all the cancer cell lines analysed except in non-tumorigenic MRC5 cells (Figure 3a) . The induction of apoptosis was celltype-specific and dose-dependent (Figures 3a and b , respectively). Consistent with the results of the proliferation experiments, the strongest effects were observed in the MOLT4-leukaemia cell line, in that 75% of the cells underwent apoptosis after 24 h of incubation with 100 mM Salermide (Figure 3a) . To investigate further whether the induction of apoptosis by Salermide is mediated by classical apoptotic pathways, we analysed the cytosolic levels of cytochrome c and activated Antitumour activity of Salermide E Lara et al caspase 3, two well-known mediators of apoptotic pathways. We found that incubation with 100 mM Salermide alone resulted in an increase of cytosolicactivated caspase 3 and a decrease of mitochondrialcytochrome c soon after 2 h of treatment, and that the levels remained elevated until 24 h of incubation, when most of the cells died. These data are evidence that Salermide alone can induce apoptosis that, in principle, could be mediated through both extrinsic and intrinsic pathways. Thus, Salermide had several antitumorigenic advantages over the earlier described class III HDAC inhibitors: firstly, it mimics the universal proapoptotic effect on cancer samples exhibited by the classical class I, II and IV HDAC inhibitors, and secondly, its proapoptotic effect is cancer-specific, as the nontumorigenic fibroblasts MRC5 were refractory to apoptosis induction in response to this drug. Finally, we were prompted to assess possible adverse effects of Salermide in vivo. To do this, we used intraperitoneal injection to administer doses of 100 ml of 100 mM of Salermide to a group of 10 nude mice over 34 days. Salermide feeding did not produce any adverse health effects in mice as monitored by diet consumption, body-weight gain, and postural and behavioural changes throughout the study. In accordance with these standards, we observed that intraperitoneal feeding of Salermide had no apparent toxicity in nude mice.
Induction of apoptosis in cancer cells by Salermide is not primarily mediated by Sirt2
Once it had been determined that Salermide antitumour activity is primarily because of the promotion of apoptosis, we decided to study the molecular mechanisms involved in this process. As Salermide has a stronger inhibitory effect on Sirt2 than on Sirt1, we first studied the role of Sirt2 in Salermide-mediated apoptosis. We knocked down Sirt2 in the MOLT4 cell line (Figure 4a, left panel) and then treated these cells with 25 mM Salermide (which corresponds to the IC50 in MOLT4 cells) ( Figure 4a , right panel). We observed that knocking down Sirt2 in MOLT4 cells alone did not affect apoptosis, and that the induction of apoptosis by Salermide was very similar in cells deficient in Sirt2 and in control cells ( Figure 4a , right panel). Thus, in spite of Salermide being more effective in vitro against Sirt2 than against Sirt1, our results suggest that its in vivo biological role is independent of Sirt2. To demonstrate further this independence, we studied the effect of Salermide on the acetylation of two primary targets of Sirt2, namely tubulin (North et al., 2003) and lysine 16 of histone H4 (K16H4) (Vaquero et al., 2006) , as well as its relationship with the induction of apoptosis. We incubated the aforementioned cancer cell lines with 25 and 100 mM Salermide for 24 h and then measured the levels of tubulin acetylation by immunoblot and quantified the global levels of acetylation of histone Antitumour activity of Salermide E Lara et al H4 by high-performance capillary electrophoresis (Fraga et al., 2005) and top-down mass spectrometry (Parks et al., 2007) . Subsequently, we compared the levels of monoacetylated lysine 16 of histone H4 by an immunoblot and tandem mass spectrometry (VillarGarea et al., 2008) . We observed that exposure to Salermide can induce slight tubulin acetylation in MOLT4 and MDA-MB-231 cells (Figure 4b ). However, Salermide does not induce tubulin acetylation in the colon-cancer cell line SW480, in which the pattern of apoptosis induction is similar to that in MDA-MB-231 cells (Figure 3a) . Thus, even when Salermide can affect Sirt2-dependent tubulin acetylation, its proapoptoticmediated antitumorigenic effect does not seem to be primarily mediated by this molecular pathway. Figure 4c ). Consistent with this, an immunoblot using antibodies against acetylated K16H4 showed a small increase of AcK16H4 in response to Salermide in only MDA-MB-231 cells (Figure 4e ). The lack of K16H4 hyperacetylation in response to Salermide was confirmed using mass spectrometry for histone H4 from Raji cells; MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) spectra show a decrease in mono-and diacetylation at the peptide 4-17 after Salermide treatment (Figure 4f ). Tandem mass spectrometry analysis of the monoacetylated Antitumour activity of Salermide E Lara et al peptide indicates that in both treated and untreated samples most of the monoacetylation occurs at K16H4 (data not shown), which indicates that Salermide treatment does not increase K16H4 acetylation in Raji cells. Thus, taken together, our results suggest that the proapoptotic antitumorigenic effect of Salermide does not seem to be primarily mediated either directly or indirectly by Sirt2. It is important to note that these results do not necessarily imply that Salermide cannot inhibit Sirt2 in vivo. However, the effect that Salermide has on other targets is probably faster and, as the cells enter apoptosis, there is insufficient time to observe the biological effects mediated by Sirt2.
Induction of apoptosis in cancer cells by Salermide is primarily mediated by Sirt1
We next focused our attention on Sirt1. Its participation in the biological response of cancer cells to Salermide is indicated by the fact that RNA interference (RNAi)-mediated knockdown of Sirt1 results in increased apoptosis in various cancer cell lines (Chen et al., 2005; Ford et al., 2005; Pruitt et al., 2006; Wang et al., 2006; Stunkel et al., 2007; Sun et al., 2007) . To show further Sirt1's specific role in inducing apoptosis in cancer cells in response to Salermide, we used RNAi methodology to knock down Sirt1 activity in the MOLT4 cell line (Figure 5a To study the involvement of Sirt1 in the apoptotic response of cancer cells to Salermide in greater depth, we examined the acetylation status of several Sirt1 targets in cells before and after treatment with 25 mM Salermide. One of the primary molecular targets of Sirt1 is p53 (Vaziri et al., 2001) . Sirt1 is able to deacetylate and inhibit p53 increasing survival in response to stress (Luo et al., 2001) . Thus, we hypothesized that inhibiting Sirt1 could activate p53 and induce apoptosis. To test this, we used immunoblot to determine the acetylation status of p53 in response to Salermide in the MOLT4, MDA-MB-231 and SW480 cell lines. Intriguingly, we observed that, as proposed earlier, MOLT4 presents very reduced levels of the p53 tumour suppressor protein (Figure 5b ; Rodrigues et al., 1990) which, given that Salermide induces apoptosis in MOLT4, rules out the possibility of a principal role for p53 in the process. We did not observe a significant increase in p53 acetylation in response to 25 mM Salermide in the MDA-MB-231 and SW480 cell lines (Figure 5b) . To examine the role of Sirt1 in p53 acetylation in greater detail, we used RNAi methodology to knock down Sirt1 activity in the MOLT4, MDA-MB-231 and SW480 cell lines (Figure 5c ). We found that interfering Sirt1 induces only a moderate increase of p53 acetylation in the MDA-MB-231 cell line. Consistent with this, treatment with 100 mM Salermide (the concentration necessary to achieve the IC50 in MDA-MB-231 cells) induced a similar increase of p53 acetylation in this breast cancer cell line (data not shown). The effect of Sirt1 on p53 acetylation in cancer is variable. Various other researchers have reported that Sirt1 inhibition can induce (Heltweg et al., 2006; Lain et al., 2008) or not induce (Ota et al., 2006) p53 acetylation in cancer cell lines. As we found induction of p53 acetylation in response to Salermide-mediated Sirt1 inhibition only in the MDA-MB-231 cell line, our results suggest that the role of Sirt1 in p53 acetylation depends on the cell type.
We found that Salermide can induce apoptosis without increasing p53 acetylation (SW480 cells) and that it can even do it in cells deficient in p53 (MOLT4). This is consistent with earlier work showing that Sirt1 inhibition in MCF-7 breast cancer cell line (Ota et al., 2006) does not induce p53 acetylation, and that RNAi-mediated knockout of Sirt1 p53-deficient HCT116 colon cancer cells induces apoptosis (Ford et al., 2005) . Overall, these observations imply that p53 may be dispensable for the induction of Sirt1-dependent apoptosis in cancer cells. This is in close agreement with the finding in Sirt1/ p53 double-knockout mice that Sirt1 does not affect p53-dependent apoptosis (Kamel et al., 2006) .
Salermide induces the reactivation of proapoptotic genes that are aberrantly repressed in cancer cells by Sirt1-mediated K16H4 deacetylation We next turned our attention to the locus-specific acetylation of lysine 16 of histone H4, the main histone target of Sirt1 (Vaquero et al., 2004) . It has recently been proposed that some of the protumorigenic effects of Sirt1 are mediated by the aberrant recruitment of Sirt1 to the promoter region of tumour supressor genes (TSGs) and subsequent aberrant epigenetic repression (Pruitt et al., 2006) . As Salermide induces massive apoptosis in less than 24 h after treatment, we formulated the hypothesis that Sirt1 was aberrantly recruited to proapoptotic genes in cancer but not in normal cells, and, as a consequence of that, these genes were aberrantly repressed in cancer cells. The treatment with Salermide would thus induce apoptosis through the inhibition of Sirt1 and consequent hyperacetylation and reactivation of these genes. To test this hypothesis, we first used the TaqMan Low Density Array Human Apoptosis Panel (Applied Biosystems) to analyse the expression status of 93 genes involved in apoptosis in the MOLT4 cancer cell line and the MRC5 fibroblasts before and after incubation with 25 mM Salermide. Intriguingly, we found that 20 of the 37 (54%) proapoptotic genes in the TaqMan Low Density Array were overexpressed (>20%) after treating the MOLT4 cells with 25 mM Salermide (Figure 5d ). Of even greater note, none of these genes was overexpressed in MRC5 cells after treatment with Salermide (Figure 5d and Supplementary Table 2 online). To confirm that the reactivation of these genes is mediated by Sirt1, we used RNAi methodology to knock down Sirt1 activity in the MOLT4 cell line and then analysed the expression status of the aforementioned 93 genes. We found that 18 of the 37 (49%) proapoptotic genes in the TaqMan Low Density Array were overexpressed (>20%) after knocking down Sirt1 activity (Figure 5d and Supplementary Table 2 online). It is also noteworthy that all of these genes were also overexpressed in MOLT4 cells treated with 25 mM Salermide (Figure 5d and Supplementary Table 2 online). As earlier argued, the greater number of proapoptotic genes reactivated with Salermide than with RNAi Sirt1 can be explained by the fact that, on average, only 70% of the MOLT4 cells become transfected with the RNAi Sirt1 construct (data not shown). Thus, the high degree of coincidence between Salermide-mediated Sirt1 inhibition and iRNAmediated Sirt1 silencing suggests that the in vivo mechanism of action of Salermide is specifically mediated through Sirt1.
To discover more about the role of Sirt1 in reactivating proapoptotic genes in response to Salermide, we used chromatin immunoprecipitation technology to assess Sirt1 occupancy and the acetylation status of K16 of histone H4 in MOLT4 cells treated or not with Salermide at the promoter region of four of the reactivated genes (CASP8, TNF, TNFRSF10B and PUMA). We found that for all these four genes, their reactivation after treatment with Salermide was associated with a substantial increase in the acetylation status of the lysine 16 of histone H4 at their promoter region (Figure 5e ). Interestingly, we detected Sirt1 in the promoter region of all four genes analysed (Figure 5e ). These observations suggest that Sirt1 may be involved in the aberrant repression of proapoptotic genes in cancer by a mechanism that prevents the acetylation of lysine 16 of the histone H4 at their respective promoters. Most of these apoptotic genes act downstream in the deathreceptor pathway, and so their aberrant epigenetic inactivation might impair the induction of apoptosis in tumour cells, which would imply that Sirt1 contributes to the promotion of cancer. The inhibition of Sirt1 with Salermide results in the reactivation of several of these genes, leading to an overall induction of apoptotic pathways as shown by the increase in cytosolic cytochrome c and cleaved caspase 3 after treatment with Salermide (Figure 3c ). Our results not only draw attention to Salermide as a promising antitumorigenic drug, but also support the hypothesis that improper Sirt1 deacetylation of lysine16 of histone H4 at cancerprotective genes might be tumorigenic (Pruitt et al., 2006) . Although our results suggest that one of the molecular mechanisms by which Salermide induces apoptosis is the reactivation of proapoptotic genes aberrantly silenced by Sirt1, we cannot exclude the possibility that, apart from the reactivation of proapoptotic genes, the induction of apoptosis by Salermide can be mediated by other Sirt1 targets, such as forkhead transcriptional factors (FOXO), p300 histone acetyltransferase, the tumour protein p73 (p73), E2F transcription factor 1, the DNA repair factor Ku antigen, 70-kDa subunit (Ku70), the nuclear factor kappa-B inhibitor and the androgen receptor (reviewed in Guarente and Picard, 2005) . Indeed, some targets, such as E2F transcription factor 1 and nuclear factor kappa-B inhibitor, are important players in the apoptotic pathways (reviewed in .
Concluding remarks
Here we describe Salermide, a reverse amide at the meta position that has a strong inhibitory activity on Sirtuins. It induces massive apoptosis in cancer but not in nontransformed cultured cells, which makes it a promising candidate as a future antitumorigenic drug. We were able to establish that the apoptotic effect of Salermide is in part because of the reactivation of proapoptotic genes that are epigenetically repressed by Sirt1 exclusively in cancer cells. This provides further clarification of the molecular mechanism by which Sirt1 exerts its oncogenic effects in cancer.
Materials and methods

3D modelling
Docking studies were performed using the genetic algorithmbased program GOLD (Jones et al., 1997) , where GoldScore was used as scoring function to rank proposed binding solutions. The available experimental information was considered to define the docking area to be explored; thus, the docking region used was a 10-Å sphere around the oxygen O of Gln167, the Sirt2 C-pocket (Finnin et al., 2001; Min et al., 2001; Avalos et al., 2005; Huhtiniemi et al., 2006) . For Salermide, all proposed solutions converged to the same binding area and mode, involving the same residues; however, different solutions emerged for sirtinol, and the five highest-ranking solutions were selected for further analyses. Thus, those complexes corresponding to the best pose for Salermide and the top five best poses for sirtinol were energyminimized under the AMBER99 force field (Ponder and Case, 2003) , using a continuum solvation model, the implicit generalized Born model (Onufriev et al., 2004 ) and a non-bonded cutoff of 18 Å . This gave the best pose for sirtinol of the top five-ranked solutions provided by GoldScore, which was very close to Salermide; in fact, the root mean square deviation between their best poses was only 5.66 Å (for heavy atoms) (Figure 1a ). The energy of interaction between Salermide and Sirt2, obtained after minimization, was À56.95 and À44.61 kcal/mol for the sirtinolSirt2 complex. The difference, around 12 kcal/mol, suggests that Salermide is a more potent inhibitor of Sirt2; this is in agreement with the ranking obtained through the docking fitness function. The higher estimated binding affinity of Salermide may be due, in part, to the polar interaction between the amidic carbonyl group and Q167, which sirtinol does not exhibit.
Ligands were allowed full flexibility during docking and minimization. In the case of the receptor, all backbone and side-chain torsion angles were allowed to move according to the potential used for minimization. Energy minimization was carried out with the MOE package (Chemical Computing Group, Inc. Molecular Operating Environment, MOE 2007 .09 (2007 , Montreal, Quebec, Canada), and the same program was used to display the schematics of the interactions between Sirt2 and the ligands (Clark et al., 2006) (Figure 1b) .
Synthesis of Salermide
Melting points were determined with the Buchi 530 melting point apparatus and were not corrected. Infrared (IR) spectra (KBr) were recorded on a Perkin-Elmer Spectrum One instrument. 1 H nuclear magnetic resonance spectra were recorded at 400 MHz with a Bruker AC 400 spectrometer, reporting chemical shifts in d (ppm) units relative to the internal reference tetramethylsilane (Me 4 Si). All compounds were routinely checked by thin-layer chromatography and 1 H nuclear magnetic resonance. Thin-layer chromatography was performed on aluminium-backed silica gel plates (Merck DC, Darmstadt, Alufolien Kieselgel 60 F 254 ) with spots visualized under ultraviolet light. All solvents were reagent grade and, when necessary, were purified and dried by standard methods. Concentrations of solutions after reactions and extractions were measured using a rotary evaporator operating at a reduced pressure of B20 torr. Organic solutions were dried over anhydrous sodium sulphate. Analytical results were within ± 0.40% of theoretical values. All chemicals were purchased from Aldrich Chimica (Milan, Italy) or Lancaster Synthesis GmbH (Milan, Italy), and were of the highest purity.
In vitro inhibition assays of Sirt1 and Sirt2
Recombinant His-tagged human Sirt1 and Sirt2 were assayed for deacetylase activity using the HDAC fluorescent activity assay (BIOMOL, Plymouth, PA, USA) (Howitz et al., 2003) . Reactions were carried out at 37 1C for 60 min. Results are expressed as the mean and standard deviation of four independent experiments.
Cell lines, culture conditions and treatments Cell lines (SW480, MDA-MB-231, MOLT4, KG1A, K562 and Raji) were obtained from the American Type Culture Collection (VA, USA). Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay as described earlier (Ropero et al., 2004) . IC50 index was calculated using four Salermide concentrations (25, 50, 75 and 100 mM) for 24 h. The percentage of apoptotic cells was determined with the FACSCalibur (BD, Heidelberg, Germany) apparatus The Annexin V FACS analysis was carried out according to the manufacturer's protocol (Annexin V-FITC, BD-Pharmingen, San Diego, CA, USA). In vivo tolerability of Salermide was studied in ten athymic (BALB/c, nu/nu) female nude mice (Harlan Sprague-Dawley, Indianapolis, IN, USA). Salermide (100 mM) was administered as described elsewhere (Herranz et al., 2006) .
Small interfering RNA interference assay MOLT4 cells were nucleofected with validated Sirt2 RNAi (SI00301805 and SI02655471, QUIAGEN, Hilden, Germany) and Sirt1 RNAi (12938-127 duo pack, Invitrogen, Carlsbad, CA, USA) using the Cell Line Nucleofector Kit L (Amaxa Biosystems, Cologne, Germany).
Western blot analysis
Cell lysates for protein analysis were prepared and analysed by western blotting using the following antibodies: anti-acetylated tubulin (1:2000, Sigma-Aldrich, St Louis, MS, USA), anti-bactin (1:10 000, Sigma-Aldrich), anti-acetyl-p53 lys382 (1:1000, CST, Danvers, MA, USA), anti-p53 monoclonal DO1 (1:2000, Oncogene Sciences, Cambridge, MA, USA), anti-a-tubulin (1:50 000, Sigma-Aldrich), anti-AcK16H4 (1:2000, Upstate, Billerica, MA, USA), anti-Sirt2 antibody (1:1000, Abcam, Cambridge, UK) and anti-Sirt1 antibody (1:1000, CST), anticaspase 3 (1:1000, CST), anti-caspase 8 (1:1000, Abcam) and anti-cytochrome c (1:1000, CST). Cytoplasmic (40 mg) and membrane (30 mg) lysates were prepared using the Calbiochem's (San Diego, CA, USA) subcellular proteome extraction kit.
High-performance capillary electrophoresis Histone H4 acetylation was quantified as described earlier (Fraga et al., 2005) . Individual histone fractions were prepared from cell nuclei and then purified by reverse-phase highperformance liquid chromatography. Acetylated histone H4 derivatives were resolved by high-performance capillary electrophoresis.
Top-down mass spectrometry High-resolution mass measurements for exact mass determination were carried out using an APEX Qe Fourier transform mass spectrometer (Bruker Daltonics Inc., Billerica, MA, USA) equipped with 9.4-T superconducting refrigerated cryomagnet and the external electrospray ion source (Dual source). The spectra were externally calibrated with an arginine cluster in positive ion mode in the mass range 350-1400 m/z. The spectra were acquired over a mass range of 200-3000 m/z using 1M data points. After sine apodization the spectra were processed with DataAnalysis 3.4 (Bruker Daltonik GmbH, Bremen, Germany) using SNAP2 for quantification.
MALDI-TOF and electrospray ionization-mass spectrometry/ mass spectrometry Histone H4 was prepared as described earlier (Villar-Garea et al., 2008) . MALDI-TOF spectra were acquired on a Voyager DE-STR station (Applied Biosystems, Weiterstadt, Germany) in positive reflector mode. Collision-induced decay spectra were recorded on a Q-STAR XL instrument (PE-Sciex, Ontario, Canada) with manually adjusted collision energies.
Quantitative RT-PCR Relative expression levels of proapoptotic genes were analysed using the TaqMan Low Density Array Human Apoptosis Panel (Applied Biosystems, Foster City, CA, USA) and the Applied Biosystems 7900HT Fast Real-Time PCR System. Data were normalized using GAPDH and b-actin as endogenous controls.
Quantitative chromatin immunoprecipitation
The chromatin immunoprecipitation assay was carried out as described earlier (Fraga et al., 2005) with anti-AcK16H4 (Active Motif, Carlsbad, CA, USA), anti-Sirt1 (CST) and anti-H3 (Abcam, Cambridge, UK) antibodies. PCR reactions were run and analysed using the Applied Biosystems 7900HT Fast Real-Time PCR System. Primers and conditions for each promoter are shown in Supplementary Table 3 online. The enrichment factor refers to the copy number of a gene of interest in the bound fraction after ChIP with the appropriate antibody divided by the copy number of that gene in the bound fraction after ChIP with the H3 antibody.
